Moderna has announced a new cost-cutting round as it tries to pare down its annual costs, with a new commitment to cut 10% off its headcount by the end of the year. The target is to reduce its ...

Levi Garraway, Roche's chief medical officer and head of global product development. Roche has built the evidence for its oral BTK inhibitor fenebrutinib in multiple sclerosis (MS) with two phase 3 ...

AstraZeneca's anticoagulant reversal agent Andexxa was given an accelerated approval by the FDA in 2018, but the company's plan to get that upgraded to a full approval is facing some pushback. At an ...

Anthropic has launched Claude for Healthcare, a suite of AI tools for health systems, payers, and patients, in the latest part of its push into the health category. The announcement – made at the ...

In June 2022, NHS England (NHSE) and the National Institute for Health and Care Excellence (NICE) launched the Innovative Medicines Fund (IMF). The £340 million fund will provide non-cancer patients ...

After a non-committal appraisal of Big Health's Sleepio app for insomnia last November in draft guidance from NICE, the cost-effectiveness agency has come out in favour of the digital therapy. The ...

Hengrui Pharma and partner Kailera have joined the ranks of companies with clinical data in hand for an oral drug for weight loss, reporting weight loss of up to 12.1% in a phase 2 trial with their ...

The pharma industry's challenge to Medicare drug price negotiation powers continues to rumble on, with three drugmakers asking a US appeals court to revive their lawsuits. Lawyers for AstraZeneca, ...

CDER director George Tidmarsh will now also take responsibility for CBER at the FDA. The FDA has moved swiftly to fill the void left by Vinay Prasad's resignation as director of the Center for ...

Bristol Myers Squibb has reached for its wallet to avoid being left behind in the race to develop a new class of bispecific antibodies for cancer that have been billed as the next big thing in ...

The FDA has added a warning label to bluebird bio's Skysona, after launching an investigation into cases of blood cancer in patients treated with the ex vivo gene therapy last November. Skysona ...

Deal-hungry Ipsen is at it again, pledging just over $1 billion for rights to an antibody-drug conjugate (ADC) for cancer developed by China's Simcere Zaiming, that is due to start clinical testing ...